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Conclusions: TAVI has provided good results in the
initial 27 patients. However, The use of transcatheter aor-
tic valve implantation should be restricted to the inoper-
able high-risk patients.
http://dx.doi:10.1016/j.jsha.2013.03.071
Downs syndrome and cardiac surgery, a dilemma,
should we operate or not?
Ghada Shiekh Abdullah, Shehla Jadoon,
Milad Elsegaier, M.O. Galal
Background: Incidence of congenital heart disease
in patients with Down syndrome (DS) is 40%. In the
past some have advocated that the cardiac defects in
DS should not be repaired, reports had shown outcome
comparable to individuals without DS. The aim of the
study is to analyze the outcome of cardiac surgery in
DS.
Methodology: We conducted a retrospective study
in the last 2 years at our institution. Patients involved
were DS less than 13 years who had cardiac surgery.
DS with chronic lung disease or unreactive pulmonary
hypertension were excluded. We analyzed their demo-
graphic data, cardiac lesion, type of surgery, ICU stay,
morbidities and mortality.
Results: 23 patients with DS (11 Females, 13 Males),
with median age of 7 months, mean age of 32month.
AVSD were (n = 15) 65%), VSD were (n = 5) 21%. Postop-
eratively, 21% were extubated on the same day. 27% had
intubation more than 9 days. Almost 30% had a hospital
stay of >15 days. Complications were respiratory prob-
lems in 45%, arrhythmias in 8% and residual AV valve
regurgitation in 8%. Hospital mortality was (n = 2/23) 8%.
Conclusion: Whether to operate Down syndrome
patients or not remains unclear. Our study showed, sig-
nificant postoperative complications, lengthy hospital
stay and relatively high mortality. Despite of this we feel
they should be given the chance of surgery to improve
their life quality.
http://dx.doi:10.1016/j.jsha.2013.03.072
Utilization of prophylactic drug therapy after acute
myocardial infarction in Abu Dhabi and Sweden
Oliver Harrison, Khaled Aidha Al Jaberi, Eman S.
Hassan, Björn Wettermark, Ana-Marija Gjurovic,
Gunnar Engström
Purpose: Pharmaceutical treatments to decrease
blood pressure and lipids, inhibit platelet aggregation,
and control diabetes are cornerstones of secondary pre-
vention after acute myocardial infarction (AMI). This
study compares the drug use during a oneyear period
post-AMI in Abu Dhabi and Sweden.
Methods: In Abu Dhabi, information on medications
dispensed during one year following a hospitalized AMI
during January 2010 to June 2011 (n = 1,326) was retrieved
from the Health Authority of Abu Dhabi’s administrative
claims database. Rates of at least one prescription within
selected classes were quantified immediately following
the event (months 0–3), 4–6 months, and 10–12 months
after the event. Similar data was collected for hospital-
ized AMI patients in Sweden during 2009 (n = 19,312),
by linkage of the Swedish Myocardial Infarction register
and Prescribed Drug Register. All proportions were age-
standardized.
Results: During the first three months post-AMI, the
proportion of patients in Abu Dhabi with at least one pre-
scription of an anti-hypertensive drug was 76%, statin
72%, platelet aggregator inhibitor 76%, beta-blocker
64%, and drugs affecting the renin-angiotensin system
only 56%. These proportions declined to 36%, 34%, 34%,
28% and 28%, respectively, during month 10-12. Reduc-
tions among UAE citizens were somewhat lower than
among expatriates. In Sweden, the corresponding pro-
portions were 90%, 82%, 89%, 83% and 68%, respectively,
10- 12 months post-AMI.
Conclusion: Abu Dhabi’s health data systems offer a
valuable tool for monitoring adherence to drug use. It
appears that the outcomes of AMI patients in Abu Dhabi
could be substantially improved by promoting adherence
to evidence-based guidelines for secondary prevention.
http://dx.doi:10.1016/j.jsha.2013.03.073
Systemic lupus erythrematosus; its implication in
cardiac surgery: Institutional case report
Hala Samir El-Mohamady ⇑
Introduction: Systemic lupus erythematosus (SLE)
is an autoimmune disease that primarily affects young
women. According to the literature, the prevalence of
cardiovascular involvement in patients with systemic
lupus erythematosus (SLE) has been estimated to be
more than 50%.
Valvular involvement is the most frequent cardiac
manifestation in SLE. Functionally, valvular regurgitation
hasbeen reported to occur in up to 74% of patients.
Meanwhile valvular endocarditis is a frequent manifesta-
tion of SLE, and the mitral valve is most frequently
affected. However, any valve or multivalvular affection
may occur.
Valvular lesions resulting from lupus can cause severe
mitral regurgitation (MR). The most classic cardiac
valvular abnormality in patientswith SLE is known as
Libman–Sacks endocarditis, which consists of
noninfective, verrucousvegetations(marantic endocardi-
tis). They occur most frequently onthe mitral valve. Most
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